Group net sales fell by 5.6% to 20,993 million euros in 2023 (-1.6% organic).

EBITDA fell by 14.2% to 5,879 million euros (-9.0% in organic terms).

' Healthcare's excellent sales and earnings performance demonstrates the benefits of Merck's diversified business model.

Earnings per share amounted to E8.49. On this basis, management will propose a dividend of E2.20 per share to the Annual General Meeting on April 26, 2024. This is in line with the previous year's dividend.

'We recorded solid results in the transition year 2023, despite difficult market conditions, demonstrating the strength of our business. Our diversified businesses will continue to benefit from attractive market growth opportunities also in the medium term', said Belén Garijo, Merck Chairman and CEO.

'Now we are fully focused on gradually returning to growth in fiscal 2024, while defining our strategic roadmap to ensure long-term profitable and sustainable growth for Merck.'

In terms of forecasts for fiscal 2024, management is targeting a return to organic growth. Sales and EBITDA growth should be slight to moderate.

Copyright (c) 2024 CercleFinance.com. All rights reserved.